Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12204134 | 0.88 | PSMB1 (0.64) | KDM4ETSHRALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL10223315 | 0.84 | MEN1 (0.62) | KDM4ETSHRTP53ALDH1A1NPC1 | |
| SCHEMBL18427237 | 0.82 | ALDH1A1 (0.56) | KDM4ETSHRTP53ALDH1A1NPC1 | |
| SCHEMBL12015748 | 0.78 | ALDH1A1 (0.64) | KDM4ETSHRALDH1A1NPC1HTT | |
| SCHEMBL982378 | 0.78 | KDM4E (0.63) | KDM4ETSHRTP53ALDH1A1NPC1 | |
| SCHEMBL14578276 | 0.77 | ALDH1A1 (0.69) | KDM4ETSHRTP53ALDH1A1NPC1 | |
| SCHEMBL12204133 | 0.76 | PSMB1 (0.83) | KDM4EALDH1A1MEN1KMT2APSMB1 | |
| SCHEMBL104326 | 0.76 | MEN1 (0.70) | KDM4EALDH1A1NPC1SMN1; SMN2LMNA | |
| SCHEMBL259183 | 0.75 | KDM4E (0.63) | KDM4ETSHRTP53ALDH1A1NPC1 | |
| SCHEMBL13107094 | 0.74 | ALDH1A1 (0.73) | KDM4ETSHRTP53ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | CNR1, CNR2, OPRD1 | KDM4E 535/4885TSHR 436/4885TP53 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.